In the news PCSK9 inhibitors and new onset diabetes - Reassuring evidence
Reassuring data have been released suggesting that PCSK9 inhibition does not increase the risk of new onset diabetes in statin treated patients.Read the article by Dr Bertrand Cariou »
Plasma PCSK9 levels not associated with metabolic risk
While elevated PCSK9 levels are not associated with increased metabolic risk, an increased ratio of PCSK9/apoB does predispose to higher risk.Read the article »
Safety of LDL-lowering in FH children
One of the questions raised about managing children with familial hypercholesterolaemia (FH, inherited high cholesterol) is the long term safety of cholesterol-lowering treatments. There has been some concern that lowering cholesterol levels could interfere with hormone production and, potentially, future fertility.
Read the article »